Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia

European Journal of Preventive Cardiology

Volumn 20, Issue 1, 2013, Pages 40-53

  Stender, Steen ^a   Budinski, Dragos ^b   Gosho, Masahiko ^c   Hounslow, Neil ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Kowa Research Europe Ltd   (United Kingdom)

^c KOWA COMPANY LTD   (Japan)

Author keywords

Cardiovascular diseases; dyslipidaemia; elderly; HMG CoA; hypercholesterolaemia; pitavastatin; statins

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RHINOPHARYNGITIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG TOLERANCE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PRAVASTATIN; QUINOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873468863     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312451251     Document Type: Article

References (28)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106: 3143-3421
2. Packard CJ, Ford I, Robertson M, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005 ; 112: 3058-3065
3. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008 ; 29: 932-940
4. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 ; 51: 1512-1524
5. Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. Br J Clin Pharmacol. 2006 ; 61: 494-501
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 ; 14: E1 - E40
7. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006 ; 112: 71-105
8. Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol. 2008 ; 1: 105-113
9. Hayashi T, Yokote K, Saito Y, et al. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007 ; 8: 2315-2327
10. Nakagawa S, Hounslow N. Pitavastatin is not subject to clinically relevant pharmacokinetic interactions when administered with CYP3A4 inhibitors in healthy volunteers. Eur Heart J. 2009 ; 30: 958 [Abstract] :
11. Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011 ; 13: 1047-1055
12. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008 ; 201: 345-352
13. Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther. 2011 ; 28: 811-823
14. Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther. 2011 ; 28: 799-810
15. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 ; 162: 373-379
16. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 ; 360: 1623-1630
17. Harley CR, Gandhi S, Blasetto J, et al. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother. 2007 ; 5: 185-194
18. Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2012 ;:
19. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 ; 89: 268-275
20. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002 ; 144: 1044-1051
21. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278
22. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010 ; 210: 202-208
23. Cea-Calvo L, Lozano JV, Fernandez-Perez C, et al. Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. Int J Clin Pract. 2009 ; 63: 71-81
24. Acharjee S, Welty FK. Atorvastatin and cardiovascular risk in the elderly - patient considerations. Clin Interv Aging. 2008 ; 3: 299-314
25. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002 ; 287: 337-344
26. Pau AK. Polypharmacy problems: drug interactions in the multidrug therapy of HIV infection. The PRN Notebook. 2002 ; 7: 4-9
27. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet) - drug use investigation. Jpn Pharmacol Ther. 2008 ; 36: 709-731
28. Teramoto T, Urashima M, Shimano H, et al. A large-scale survey on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia. Jpn Pharmacol Ther. 2011 ; 39: 789-803